HIM
HRMY icon

Hillsdale Investment Management’s Harmony Biosciences HRMY Stock Holding History

Hillsdale Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-137,400
Closed -$3.85M – 705
2026
Q1 		$3.85M Hold
137,400
– – 0.1% 243
2025
Q4 		$5.14M Hold
137,400
– – 0.14% 194
2025
Q3 		$3.79M Buy
137,400
+16,700
+14% +$575K 0.11% 243
2025
Q2 		$3.81M Buy
120,700
+50,500
+72% +$1.62M 0.14% 207
2025
Q1 		$2.33M Buy
70,200
+2,200
+3% +$78.9K 0.12% 199
2024
Q4 		$2.34M Buy
68,000
+300
+0.4% +$10.3K 0.12% 205
2024
Q3 		$2.71M Buy
67,700
+900
+1% +$31.6K 0.21% 177
2024
Q2 		$2.02M Sell
66,800
-2,800
-4% -$84.2K 0.16% 194
2024
Q1 		$2.34M Buy
69,600
+5,700
+9% +$183K 0.18% 180
2023
Q4 		$2.06M Sell
63,900
-300
-0.5% -$8.37K 0.17% 182
2023
Q3 		$2.1M Hold
64,200
– – 0.19% 170
2023
Q2 		$2.26M Sell
64,200
-11,400
-15% -$394K 0.21% 160
2023
Q1 		$2.47M Hold
75,600
– – 0.21% 144
2022
Q4 		$4.17M Buy
+75,600
New +$4.16M 0.35% 110

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hillsdale Investment Management's HRMY Position: Q2 2026 in Review

Hillsdale Investment Management sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 137,400 shares — an estimated $3.85M sold.

Hillsdale Investment Management first reported a position in HRMY in Q4 2022 and held it in 14 quarters. The position peaked at $5.14M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Hillsdale Investment Management reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 137,400 Harmony Biosciences shares in Q2 2026, an estimated $3.85M.
  • Hillsdale Investment Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 14 quarters.
  • Hillsdale Investment Management's Harmony Biosciences position peaked at $5.14M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.